In preclinical models, blocking CCL2-CCR2 signaling by genetic approach or small molecular inhibitors resulted in reduced tumor growth and metastasis and improved the efficacies of chemotherapy, radiation therapy, and immunotherapy in HCC 166-168. This evidence concerns the gene CCL2 and hepatocellular carcinoma.